163 related articles for article (PubMed ID: 33026592)
1. Small Molecule Destabilizer of β-Catenin and Ras Proteins Antagonizes Growth of K-Ras Mutation-Driven Colorectal Cancers Resistant to EGFR Inhibitors.
Choi JK; Cho H; Moon BS
Target Oncol; 2020 Oct; 15(5):645-657. PubMed ID: 33026592
[TBL] [Abstract][Full Text] [Related]
2. A Small Molecule Promoting Neural Differentiation Suppresses Cancer Stem Cells in Colorectal Cancer.
Choi JK; Kwak IS; Yoon SB; Cho H; Moon BS
Biomedicines; 2022 Apr; 10(4):. PubMed ID: 35453609
[TBL] [Abstract][Full Text] [Related]
3. KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer.
Cho YH; Cha PH; Kaduwal S; Park JC; Lee SK; Yoon JS; Shin W; Kim H; Ro EJ; Koo KH; Park KS; Han G; Choi KY
Oncotarget; 2016 Dec; 7(49):81727-81740. PubMed ID: 27835580
[TBL] [Abstract][Full Text] [Related]
4. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
Lee SK; Cho YH; Cha PH; Yoon JS; Ro EJ; Jeong WJ; Park J; Kim H; Il Kim T; Min DS; Han G; Choi KY
Exp Mol Med; 2018 Nov; 50(11):1-12. PubMed ID: 30459318
[TBL] [Abstract][Full Text] [Related]
5. Interaction of the Wnt/β-catenin and RAS-ERK pathways involving co-stabilization of both β-catenin and RAS plays important roles in the colorectal tumorigenesis.
Lee SK; Hwang JH; Choi KY
Adv Biol Regul; 2018 May; 68():46-54. PubMed ID: 29449169
[TBL] [Abstract][Full Text] [Related]
6. Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling.
Moon BS; Jeong WJ; Park J; Kim TI; Min do S; Choi KY
J Natl Cancer Inst; 2014 Feb; 106(2):djt373. PubMed ID: 24491301
[TBL] [Abstract][Full Text] [Related]
7. TRIB3 Interacts With β-Catenin and TCF4 to Increase Stem Cell Features of Colorectal Cancer Stem Cells and Tumorigenesis.
Hua F; Shang S; Yang YW; Zhang HZ; Xu TL; Yu JJ; Zhou DD; Cui B; Li K; Lv XX; Zhang XW; Liu SS; Yu JM; Wang F; Zhang C; Huang B; Hu ZW
Gastroenterology; 2019 Feb; 156(3):708-721.e15. PubMed ID: 30365932
[TBL] [Abstract][Full Text] [Related]
8. A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine kinase inhibitor in KRAS-mutated non-small cell lung cancer.
Park J; Cho YH; Shin WJ; Lee SK; Lee J; Kim T; Cha PH; Yang JS; Cho J; Min DS; Han G; Lee HY; Choi KY
Sci Rep; 2019 Jan; 9(1):648. PubMed ID: 30679620
[TBL] [Abstract][Full Text] [Related]
9. Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation.
Cha PH; Cho YH; Lee SK; Lee J; Jeong WJ; Moon BS; Yun JH; Yang JS; Choi S; Yoon J; Kim HY; Kim MY; Kaduwal S; Lee W; Min do S; Kim H; Han G; Choi KY
Nat Chem Biol; 2016 Aug; 12(8):593-600. PubMed ID: 27294323
[TBL] [Abstract][Full Text] [Related]
10. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
11. Identification of Ras-degrading small molecules that inhibit the transformation of colorectal cancer cells independent of β-catenin signaling.
Shin W; Lee SK; Hwang JH; Park JC; Cho YH; Ro EJ; Song Y; Seo HR; Choi KY
Exp Mol Med; 2018 Jun; 50(6):1-10. PubMed ID: 29884842
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic KRAS signalling promotes the Wnt/β-catenin pathway through LRP6 in colorectal cancer.
Lemieux E; Cagnol S; Beaudry K; Carrier J; Rivard N
Oncogene; 2015 Sep; 34(38):4914-27. PubMed ID: 25500543
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous destabilization of β-catenin and Ras via targeting of the axin-RGS domain as a potential therapeutic strategy for colorectal cancer.
Cha PH; Choi KY
BMB Rep; 2016 Sep; 49(9):455-6. PubMed ID: 27470214
[TBL] [Abstract][Full Text] [Related]
14. Histone Demethylase JMJD2D Interacts With β-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Peng K; Kou L; Yu L; Bai C; Li M; Mo P; Li W; Yu C
Gastroenterology; 2019 Mar; 156(4):1112-1126. PubMed ID: 30472235
[TBL] [Abstract][Full Text] [Related]
15. Small molecule-induced simultaneous destabilization of β-catenin and RAS is an effective molecular strategy to suppress stemness of colorectal cancer cells.
Cho YH; Ro EJ; Yoon JS; Kwak DK; Cho J; Kang DW; Lee HY; Choi KY
Cell Commun Signal; 2020 Mar; 18(1):38. PubMed ID: 32143715
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
[TBL] [Abstract][Full Text] [Related]
17. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
18. The addition of celecoxib improves the antitumor effect of cetuximab in colorectal cancer: role of EGFR-RAS-FOXM1-β- catenin signaling axis.
Valverde A; Peñarando J; Cañas A; López-Sánchez LM; Conde F; Guil-Luna S; Hernández V; Villar C; Morales-Estévez C; de la Haba-Rodríguez J; Aranda E; Rodríguez-Ariza A
Oncotarget; 2017 Mar; 8(13):21754-21769. PubMed ID: 28423516
[TBL] [Abstract][Full Text] [Related]
19. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.
Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J
Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314
[TBL] [Abstract][Full Text] [Related]
20. Silibinin suppresses growth of human colorectal carcinoma SW480 cells in culture and xenograft through down-regulation of beta-catenin-dependent signaling.
Kaur M; Velmurugan B; Tyagi A; Agarwal C; Singh RP; Agarwal R
Neoplasia; 2010 May; 12(5):415-24. PubMed ID: 20454513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
